



**KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LIMITED
BENGALURU**

"GLOBAL TENDER NOTICE"

**TECHNOLOGY TRANSFER
FOR
CEPHALOSPORIN-C (INTERMEDIATE)/
7-AMINOCEPHALOSPORANIC ACID (7-ACA)
BULK DRUG PROJECT**

CAPACITY/ANNUM:1000 METRIC TONNE/ANNUM

TENDER No.: KAPL/BDP/SR/2070



**KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LIMITED
BENGALURU**

CONTENTS

SCHEDULE	3
1. DEFINITIONS	4
2. ABBREVIATIONS	4
3. LANGUAGE OF TENDER	4
4. ELIGIBLE TENDERERS	5
5. TENDERING EXPENSE.....	5
6. AMENDMENTS TO THE DOCUMENTS.....	5
7. EARNEST MONEY	5
8. SUBMISSION OF BIDS.....	6
9. EVALUATION OF TENDERS.....	7
10. INSTRUCTIONS TO BIDDER	8
11. BRIEF ABOUT THE COMPANY	11
12. OBJECTIVE	11
13. CRITERIA FOR SELECTION OF "TECH TRANSFER COMPANY"	11
14. SCOPE OF WORK FOR TECHNOLOGY TRANSFER COMPANY CEPHALOSPORIN C, 7ACA ENZYMATIC PROCESS AND ENZYME PROCESS (CONFIRMATION TO BE GIVEN IN THE TECHNICAL BID)	13
15. TERMS OF PAYMENT.....	27
16. LIQUIDATED DAMAGE.....	27
17. PERFORMANCE GUARANTEE & WARRANTY.....	27



**KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LIMITED
BENGALURU**

SCHEDULE

RFP Issuance Date	13/12/2023														
Last Date for Submitting queries	23/12/2023, 11:00 Hours IST														
Pre Bid meeting	Video Conference Link will be available one day before the pre-bid meeting (26/12/2023, 11:00) at www.kaplindia.com .														
E-mail for prebid queries	7acaproject@kaplindia.com														
Last Date of Response to Queries (Closing Date)	28/12/2023, 18:00 Hours IST														
Last Date of Bid Submission	05/01/2024, 18:00 Hours IST														
Opening of Technical Bids	08/01/2024, 11:00 Hours IST														
Intimation of Corrigendum Adendum, if any	Will be notified on KAPL websites only.														
Bid Submission	"HOD Purchase" M/s Karnataka Antibiotics and Pharmaceuticals Limited, Plot No.14, II Phase Peenya Industrial Area, Bangalore – 560 058. India.														
Opening of Tender	M/s Karnataka Antibiotics and Pharmaceuticals Limited, KAPL HOUSE "ARKA – THE BUSINESS CENTRE", Plot No. : 37, Site No. : 34/4, NTTF Main Road, Peenya Industrial Area, 2nd Phase, Bangalore – 560 058.														
Bid Validity	150 days from the last date of submission of Bids														
EMD (Indian Rupees or equivalent foreign currencies / Bank Guarantee / Letter of Credit)	Rs. 5,00,000/- (Rupees Five Lakhs only) Indian or equivalent foreign currencies. Bank details are as under:- <table border="1"><tr><td>Bank Name:</td><td>State Bank of India</td></tr><tr><td>Address of Bank:</td><td>Local Head Office Complex, 2nd Floor Above SPB Branch St.Marks Road, Bengaluru-560001.</td></tr><tr><td>Account Holder Name:</td><td>Karnataka Antibiotics and Pharmaceuticals Ltd</td></tr><tr><td>Bank Account No.:</td><td>10503342610</td></tr><tr><td>Swift Code:</td><td>SBININBB704</td></tr><tr><td>MICR Code:</td><td>560002139</td></tr><tr><td>Bank IFSC Code:</td><td>SBIN0011349</td></tr></table>	Bank Name:	State Bank of India	Address of Bank:	Local Head Office Complex, 2nd Floor Above SPB Branch St.Marks Road, Bengaluru-560001.	Account Holder Name:	Karnataka Antibiotics and Pharmaceuticals Ltd	Bank Account No.:	10503342610	Swift Code:	SBININBB704	MICR Code:	560002139	Bank IFSC Code:	SBIN0011349
Bank Name:	State Bank of India														
Address of Bank:	Local Head Office Complex, 2nd Floor Above SPB Branch St.Marks Road, Bengaluru-560001.														
Account Holder Name:	Karnataka Antibiotics and Pharmaceuticals Ltd														
Bank Account No.:	10503342610														
Swift Code:	SBININBB704														
MICR Code:	560002139														
Bank IFSC Code:	SBIN0011349														
Date of Completion of 1 st Commercial Batch	31/10/2024														
Email Address (for Technical Clarifications)	gmpant@kaplindia.com 7acaproject@kaplindia.com														

Note: In case any of the above dates fall on Saturday / Sunday / Statutory / Public Holiday, the first working dates following such date shall be considered for the purpose of this RFP.



KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LIMITED BENGALURU

1. DEFINITIONS

- 1.1. "Purchaser" means Karnataka Antibiotics and Pharmaceutical Limited
- 1.2. "Tender" means Bids / Quotation / Tender received from a Firm / Tenderer / Bidder.
- 1.3. "Tenderer" means Bidder/ the Individual or Firm submitting Bids / Quotation / Tender.
- 1.4. "Earnest Money Deposit" (EMD) means Bid Security/ monetary or financial guarantee to be furnished by a tenderer along with its tender.
- 1.5. "Contract" means the written agreement entered into between the purchaser and/or consignee and the supplier, together with all the documents mentioned therein and including all attachments, annexures etc. therein.
- 1.6. "Day" means calendar day

2. ABBREVIATIONS

- 2.1. "GIT" means General Instructions to Tenderers
- 2.2. "PSU" means Public Sector Undertaking
- 2.3. "BG" means Bank Guarantee
- 2.4. "TE Document" means Tender Enquiry Document
- 2.5. "EMD" means Earnest Money Deposit
- 2.6. "KAPL" means Karnataka Antibiotics & Pharmaceuticals Limited
- 2.7. "KSM" means Key Starting Material
- 2.8. "cGMP" means Current Good Manufacturing Practices
- 2.9. "MSEs" means Micro and Small Enterprises
- 2.10. "MSME" means Micro, Small and Medium Enterprises
- 2.11. "DIPP" means Department of Industrial Policy & Promotion
- 2.12. "GTE" means Global Tender Enquiry
- 2.13. "DPIIT" means Department for Promotion of Industry and Internal Trade.
- 2.14. "TC" means Tender Committee.

3. LANGUAGE OF TENDER

The tender submitted by the tenderer and all subsequent correspondence and documents relating to the tender exchanged between the tenderer and the purchaser shall be written



**KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LIMITED
BENGALURU**

in the English language unless otherwise specified in the Tender Enquiry. However, the language of any printed literature furnished by the tenderer in connection with its tender may be written in any other language provided the same is accompanied by an English translation and, for purposes of interpretation of the tender, the English translation shall prevail.

4. ELIGIBLE TENDERERS

This invitation for tenders is open to all suppliers who fulfil the eligibility criteria specified in these documents.

5. TENDERING EXPENSE

The tenderer shall bear all costs and expenditures incurred and/or to be incurred by it in connection with its tender including preparation, mailing and submission of its tender and for subsequent processing the same. However, the purchaser will, in no case be responsible or liable for any such cost, expenditure etc., regardless of the conduct or outcome of the tendering process.

6. AMENDMENTS TO THE DOCUMENTS

- 6.1. At any time prior to the deadline for submission of tenders, the purchaser may, for any reason deemed fit by it, modify the TE documents by issuing suitable amendment(s) to it.
- 6.2. Such an amendment will be notified/Published only through KAPL's website <http://www.kaplindia.com>.
- 6.3. In order to provide reasonable time to the prospective tenderers to take necessary action in the submission of their tenders as per the amendment, the purchaser may, at its discretion extend the deadline for the submission of tenders and other allied time frames, which are linked with that deadline.

7. EARNEST MONEY

- 7.1. The EMD/ Bid guarantee for the amount stipulated shall accompany the tender technical bid of the tender in Indian Rupee or an equivalent amount of the currencies of the country of the tenderer. The EMD/ Bid guarantee shall be in anyone of the following alternative forms subject to the approval of the purchaser.



**KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LIMITED
BENGALURU**

- a. A crossed Bank draft in favour of Karnataka Antibiotics and Pharmaceuticals Limited payable at Bengaluru from any scheduled commercial banks.
 - b. An irrevocable bank guarantee or irrevocable letter of credit (LC) (in equivalent foreign exchange amount) issued/confirmed from any of the scheduled commercial banks in India in favour of Karnataka Antibiotics and Pharmaceuticals Limited payable at Bengaluru.
- 7.2. Those bidders registered under Micro and Small Enterprises (MSEs) or Startups as recognized by the Department of Industrial Policy & Promotion (DIPP) are exempted from depositing EMD. For claiming exemption bidder shall provide NSIC Certificate.
- 7.3. For claim exemption from depositing earnest money, the tenderer should be registered with MSME or Startups as recognized by the Department of Industrial Policy & Promotion (DIPP) are required to submit the proof.
- 7.4. EMD shall be paid online as per the bank details provided in the tender schedule.
- 7.5. Bidders are required to furnish EMD details/Proof of Payments along with the **"TECHNICAL BID"**.
- 7.6. No interest will be payable by the purchaser on the Earnest Money/Bid Guarantee.
- 7.7. The Earnest Money/Bid Guarantee deposited is liable to be forfeited if the tenderer withdraws or amends, impairs or derogates from the tender in any respect within the period of validity of his offer.
- 7.8. The earnest money of all unsuccessful tenderers will be returned by the KAPL
- 7.9. The Earnest Money Deposit of the successful tenderer will be released after 45 days of validity of the bid period(150 days).

8. SUBMISSION OF BIDS

- 8.1. Interested parties shall submit their bids in two separate sealed envelopes, i.e. technical bid and commercial bid.
- 8.2. The technical bid shall be sent in a separate sealed envelope superscribed as **"TECHNICAL BID"** along with the Tender number and date on the top of the envelope. Technical Bid shall contain the un-priced tender consisting of EMD details/Proof of Payments, **COMPLETE TECHNICAL SPECIFICATION** including drawings and documents and technical aspects of the tender such as equipment data sheets, tests and



**KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LIMITED
BENGALURU**

inspection, makes of materials, technical description, drawings etc. In addition, other Certificates / Declarations, as per Annexures enclosed, are to be submitted.

8.3. The commercial bid shall be sent in a separate sealed envelope superscribed as "**COMMERCIAL BID**" along with the Tender number and date on top of the envelope.

8.4. The bidder should put the above two sealed envelopes, i.e. Technical Bid and Commercial Bid in a bigger envelope duly sealed and submit the same to the below-mentioned address.

8.5. All bids should be addressed to

"HOD Purchase"

M/s Karnataka Antibiotics and Pharmaceuticals Limited,

Plot No.14,

II Phase Peenya Industrial Area,

Bangalore-560 058.

India.

8.6. Modification and withdrawal of bids: The bidder may modify or withdraw his bid after submitting the same prior to the Deadline prescribed for submission of bids. Bid cannot be modified subsequent to the deadline for submission of bids. No bid may be withdrawn in the interval between the deadline for submission of bids and the expiration of the period of bid validity specified by the bidder in the bid form. Withdrawal of a bid during this interval may result in forfeiture of the Bidder's bid security.

8.7. Clarification of Bids/Shortfall of Documents: During evaluation and comparison of bids, KAPL may ask the bidder for clarification on the bid. The request of clarification shall be given in writing (email/registered post) asking the tenderer to respond by a specific date. If the tenderer doesn't comply or respond by the specific date his tender/bid is liable to be rejected.

9. EVALUATION OF TENDERS

9.1. Tenders will be evaluated on the basis of the TE document, based on which tenders have been received and the terms, conditions etc., mentioned by the tenderers in their tenders. No new condition will be brought in while scrutinizing and evaluating the tenders.



KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LIMITED BENGALURU

- 9.2. KAPL has the sole discretion/Authority to reject any bids which does not comply with the requirement of this tender/If supporting documents are not furnished with the Pre-Qualification Criteria (POC)/Any discrepancy observed in the submitted documents.
- 9.3. Screening of bid documents shall be carried out by a Tender Committee constituted by the Managing Director, KAPL, as per Pre-Qualification criteria mentioned in the GTE document and based on verification of documents submitted.
- 9.4. All the prices and other information's like documents etc., having bearing on the price shall be written in both numbers and words in the prescribed offer form. In case of any discrepancy in rates quoted in words and numbers, the rate quoted in words shall be considered.

10. INSTRUCTIONS TO BIDDER

10.1. Documents to be Furnished

Bidders are requested to go through all pre-qualification requirements, the scope of licensing for execution & requirements w.r.t technical/financial capabilities for acceptance and submission of documents for verification by KAPL.

The list of documents to be furnished are:

- Authorization Letter (Format-1)
- Declaration (Format-2)
- Applicant Profile for Technology Transfer (Format-3)
- Strength & Merits of the Applicant (Format-4)
- Undertaking with regard to Blacklisting (Format-5)
- Undertaking with regard to Non-Litigation (Format-6)
- Price Bid (Format-7)
- Self Declaration Certificate (Format-8)

10.1.1. Note to the Bidder(s)

10.1.1.1. All pages of the Tender should be page numbered and indexed.

10.1.1.2. It is the responsibility of the tenderer to go through the TE document to ensure furnishing all required documents in addition to the above, if any.

10.1.1.3. The Bidder should submit the tender document as such with the seal of the company and a signed copy.



**KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LIMITED
BENGALURU**

- 10.1.1.4. Any Innovator or Bidder from a country which shares a land border with India will be eligible to bid in this tender only if the bidder is registered with the Competent Authority (i.e. Registration Committee constituted by the Department for Promotion of Industry and Internal Trade (DPIIT)).The same is available at the website <https://doe.gov.in/procurement-policy-divisions>. Bidders must submit Self Declaration Certificate as Tender "Format – 8".
- 10.2. Each page of the Bid should be serially numbered consecutively, bear the Bid number, and be signed by the tenderer (Authorized Signatory) at the bottom. In addition, a reference to the total number of pages comprising the offer should be made at the top right-hand corner of the first page.
- 10.3. Any other information which the bidder may like to provide.
- 10.4. KAPL reserves the right to call for any clarifications confined in the broad scope wherever such a clarification becomes necessary for proper judgment in evaluation.
- 10.5. Price Bid should contain complete scope with stage-wise fees. Please note – it should be linked with the performance and the yield of the master seed as per the claim.
- 10.6. In the event of any controversy or claim arising out of or relating to any provision of the contract, the parties shall try to settle such dispute or claim amicably between themselves. If failing, to any dispute/Allegation made either by the purchaser or finalized bidder shall be settled in accordance with the Indian Arbitration & Conciliation Act, 1996, the rules there under and any statutory modifications or re-enactments thereof shall apply to the arbitration proceedings. The venue of the arbitration shall be in Bengaluru, India. The award thereof shall be final and binding on the parties.
- 10.7. The place of court jurisdiction would be Bengaluru, India.
- 10.8. Finalized bidder should give Technical Assistance to the purchaser by email or phone to solve technical troubleshooting within 24 hours of the request. If required, the purchaser can invite the finalized bidder onsite to solve the problem.



**KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LIMITED
BENGALURU**

10.9. Responsibility of the Innovator:

10.9.1 MOU will be made with KAPL and Technology provider (Innovator) for lab scale trial and should also support achieving the required claim to Indian Counter Part till the commercial scale-up batches.

10.9.2 The innovator will assist the Indian Counter Part for performing a lab-scale trial 25 L to 500 L, pilot scale – 25 KL and three commercial validation batches - 250 KL in India (at KAPL).

10.10. Responsibility of the Indian Counter Part:

10.10.1. MOU will be made with KAPL and Indian Counter Part covering all activities

- a. Technology transfer from the innovator
- b. Repetition of the technology performance in India (lab-scale trial- Upstream & Downstream and Enzymatic conversion Ceph C to 7 ACA)
- c. The Lab trail in India including providing of the Lab facility will be in the scope of Indian Counterpart.
- d. Pilot scale trial in 25 KL (Upstream, Downstream and Enzymatic conversion Ceph C to 7 ACA). The Pilot Plant trail shall be conducted in KAPL facility in Ujjain.
- e. Three commercial validation batches at 250 KL followed by Downstream & Enzymatic conversion Ceph C to 7 ACA (Cephalosporin C & 7 ACA) in India (at KAPL).
- f. Complete protocol for Cephalosporin C to 7 ACA enzymatic conversion. Also, demonstration of three batches on a commercial scale. The outcome of the Cephalosporin C from 25 KL fermentor shall be Pilot batches. The outcome of Cephalosporin C from 250 KL fermentor shall be commercial batches.
- g. Engineering support for all streams (Upstream, Downstream, Enzymatic conversion Ceph C to 7 ACA, Utilities, Effluent Treatment Plant).

10.10.2. The Indian Counter Part shall be a bridge between the innovator and the KAPL until the project is completed.

10.10.3. All the activities shall be completed within 09 to 12 months after the work order placement.



KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LIMITED BENGALURU

11. BRIEF ABOUT THE COMPANY

- 11.1. Karnataka Antibiotics & Pharmaceuticals Limited (KAPL), a Government of India Enterprise under the Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals.
- 11.2. The company was incorporated in 1981 on the Hathi Committee's recommendations to supply life-saving drugs to the general public at an affordable price.
- 11.3. The plant started its commercial production in 1984.
- 11.4. We are a PIC/S GMP Certified, ISO 9001:2015; ISO 14001:2015; ISO 45001:2018 & WHO-GMP accredited company.
- 11.5. The Existing factories are located in Bengaluru & Dharwad, India. The upcoming factory is at Ujjain, India.
- 11.6. The Corporate office is located at KAPL HOUSE "ARKA – THE BUSINESS CENTRE", Plot No. : 37, Site No. : 34/4, NTTF Main Road, Peenya Industrial Area, 2nd Phase, Bangalore-560 058, which is located 1 km away from the factory site.

12. OBJECTIVE

- 12.1. This document aims to define the scope of work to be handled by the Technology (Tech) Transfer Company regarding the Process Engineering and Process Technology Transfer for the project of Cephalosporin-C (Intermediate) & 7-ACA, which KAPL proposed to start at Vikram Udyogpuri, Ujjain (Madhya Pradesh), India.
- 12.2. This document provides the expected deliverables, roles and responsibilities of the Technology Transfer Company at various stages of the project.

13. CRITERIA FOR SELECTION OF "TECH TRANSFER COMPANY"

- 13.1. The Indian counterpart Company shall have a minimum of 5 years of experience in handling and executing of fermentation-based API projects.

OR

The team members associated with the technology transfer company shall have a minimum of 5 Years of experience in handling and executing fermentation-based API projects.

- 13.2. The technology provider (Innovator) shall have experience in executing Cephalosporin-C (Intermediate) & 7-Aminocephalosporanic acid (7-ACA) products. Extra weightage



**KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LIMITED
BENGALURU**

will be given for innovators having experience more than 10 years during technical bid evaluation.

- 13.3. The Annual Average Financial turnover of the bidders (Applicable for the Indian Counterpart) during the last three years ending 31st March of the previous financial year should be atleast INR 50 Lakhs or in equivalent foreign currency.
- 13.4. The Indian counterpart company should have experience on similar classical fermentation-based API on a large scale, i.e., a minimum of 50 KL.

OR

The team members associated with the technology transfer company should have successfully experienced classical fermentation-based API on a large scale, i.e., a minimum of 50KL .

- 13.5. KAPL reserves the right to carryout the due diligence of the technology provider and their Indian Counter Part during the technical review.
- 13.6. Technology provider/Innovator shall have thorough process know-how of biological and fermentation-based Key Starting Material (KSM) plant and must have process know-how of Cephalosporin-C (Intermediate) & 7-ACA.
- 13.7. Indian Counter Part shall have 5-year experience or technical and competent manpower for handling the various areas of the project.
- 13.8. Process Technology/design shall meet cGMP requirements.
- 13.9. The Technology provider/Innovator shall furnish the following details.
 - a. Data Sheet/Claim Sheet along with the offer

Cephalosporin-C (Intermediate)		
Claimed Titer Value / Activity (G/L)	Lab Shake flask	---- G/L
	Lab Fermenter (25 L to 500 L)	---- G/L
	Pilot Fermenter (25 KL)	---- G/L
	Commercial Fermenter (250 KL)	---- G/L
Claimed DSP Recovery (%)	Lab Shake flask	---- %
	Lab Fermenter (25 L to 500 L)	---- %
	Pilot Fermenter (25 KL)	---- %
	Commercial Fermenter (250 KL)	---- %

7-Aminocephalosporanic acid (7-ACA)		
Claimed Value (%)	Lab Scale	---- %
	Pilot Scale	---- %
	Commercial Scale	---- %



**KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LIMITED
BENGALURU**

7-ACA Enzyme Details		
Claimed (Units)	Lab Scale	---- Units
	Pilot Scale	---- Units
	Commercial Scale	---- Units
Recovered (Units)	Lab Scale	---- Units
	Pilot Scale	---- Units
	Commercial Scale	---- Units

The Output of One batch _____ Kgs@250KL Fermenter – Final Product of 7-ACA.

The Output of 7-ACA with Eight No. of 250 KL Fermenter _____ Tons/Year.

The bidder must fill up the above claim sheet for technical evaluation, and it should be for the lab stage, Pilot Plant stage, and scale-up commercial batch stage. So there are three different claim sheets along with the BID.

- b. KAPL proposed to use 8 nos of 250 KL fermenter for desired output upto 1000 MT/year.
- c. Data to be furnished after order placement
 - i. Details raw material specification and requirement/Consumption details.
 - ii. Utility Equipment's including capacity, configuration and Utilities (Power, Steam, Compressed Air, Chilled Water, Brine, etc.) requirements for commercial production.
 - iii. Detail process equipment's (Fermentation, Down Stream, Enzymatic Process, etc.) requirements for commercial production. The proposed capacity of the lab fermenter, Pilot fermenter, Seed Vessels, main fermenter, Filtration/Down Stream equipment's, etc.
 - iv. Any other data required for installation of plant for getting the desired output of the plant.

14. SCOPE OF WORK FOR TECHNOLOGY TRANSFER COMPANY CEPHALOSPORIN C, 7ACA ENZYMATIC PROCESS (CONFIRMATION TO BE GIVEN IN THE TECHNICAL BID)

- 14.1. Providing master culture, maintenance & propagation.
- 14.2. Providing preservation details protocol with guaranteed yield.
- 14.3. Culture characterization as per regulatory requirement (Phenotype-Genotype and source)



**KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LIMITED
BENGALURU**

- 14.4. Process know-how with the latest technology. (Microbiology, Upstream, Downstream, Analytical and if any additional is required).
- 14.5. Production of Cephalosporin-C (Intermediate) by fermentation process and (7-ACA) 7-Aminocephalosporanic acid by enzymatic conversion in lab demo, provide technology with master culture, demo in their lab, providing technical support to Indian counterpart for Cephalosporin- C and (7-ACA) 7-Aminocephalosporanic acid by enzymatic conversion product in lab demo, support for pilot plant and commercial batch and also providing necessary document, dossier with required testing reports for transfer of Master seed and technology
- 14.6. Indian partner will be responsible for adopting the technology doing lab demonstration in India, demonstration of pilot plant batches and three commercial batches at commercial scale / plant with providing necessary raw material , instrument and process equipment. And support for 10 commercial exhibit batches, which will be taken out at KAPL by KAPL team at commercial plant at VUI, Ujjain.
- 14.7. Indian agency should responsible for necessary process engineering based on process technology , automation, process equipment capacity and specification, process P&ID from Cephalosporin-C and enzymatic conversion to 7 ACA including raw material specification, raw material consumption, utilites, quality and quantity requirement , stage wise process critical parameter, process providing to KAPL. Providing training to KAPL team for production, process, QA , QC documentation etc.
- 14.8. All equipment sizing and QC equipment require should be suitable for 1000 Mt/Year for 7-ACA production.
- 14.9. If there is any breakage or spillage of the master seed/cell during the transportation/ technology transfer then the Indian Counter Part/Innovator company should take responsibility for providing the new master seed/cell.



**KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LIMITED
BENGALURU**

DISCLAIMER

KAPL may, at its discretion or as a result of a query, suggestion, comment of the offerer, may modify the GTE documents by issuing an amendment or a corrigendum at any time before opening the GTE. Any such amendment or corrigendum will be uploaded on KAPL's website <http://www.kaplindia.com> and the same will be binding on all the bidders, as the case may be.

KAPL, at its discretion, may extend the due date of submission of GTE, and the decision of KAPL in this respect would be final and binding on the respondents. In the event of changes in the schedule, KAPL shall notify the same only through its website <http://www.kaplindia.com>. Interested respondents are advised to check the above website regularly for corrigendum/addendum, if any, which will be published only on the website.

KAPL at its discretion may cancel the GTE as deemed necessary in the company's best interest without assigning any reasons thereof.

If at any time during the examination, evaluation, and comparison of GTE, KAPL, at its discretion, can ask the bidder for clarification of its GTE. The request for clarification and the response shall be in writing.

All cost and expenses associated with the preparation and submission of the GTE response shall be borne by the bidder. KAPL shall not be responsible for any late receipt of applications for any reasons whatsoever.

KAPL engages no agent/agents or third party/parties in this process. Therefore, it is advised to deal directly with the KAPL representative who is a signatory to this document.

Conditional offers will be summarily rejected.

KAPL reserves the right to reject any bids without assigning any reasons thereof.

KAPL may relax or waive any of the conditions stipulated in this document as deemed necessary in the company's best interest without assigning any reasons thereof.



**KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LIMITED
BENGALURU**

Format-1

AUTHORIZATION LETTER

(To be submitted on Bidder Letter Head)

To,

HOD Purchase
Karnataka Antibiotics and Pharmaceuticals Limited
Plot No.14, II Phase,
Peenya Industrial Area,
Bangalore-560 058.
India.

Subject: Letter for Authorized Signatory

Ref. No. Ref: GTE No. _____ dated _____ 2023.

Sir,

This has reference to your above mentioned GTE for _____
_____. Mr./Miss/Mrs/Dr _____

is here by authorized to submit the GTE documents and participate in the processing on behalf
of M/s(Bidder Company Name). The specimen signature is attested below:

Name: _____

(Specimen Signature of Representative)

Yours faithfully,

(Signature of the Authorized signatory)

Name:

Designation:

Seal:

Date:

Place:

DECLARATION*(To be submitted on Bidder Letter Head)*

To,
 HOD Purchase
 Karnataka Antibiotics and Pharmaceuticals Limited
 Plot No.14, II Phase,
 Peenya Industrial Area,
 Bangalore-560 058.
 India.

Subject: Submission of Bidder details for transfer of technology.

M/s.....(Bidder Company Name)

Ref. No.: GTE No. dated

Sir,

The undersigned have read and examined in detail all the GTE documents pertaining to your transfer of technology do hereby express an interest in undertaking the manufacture of the product as mentioned in the GTE document. The details of the Company and contact person are given below:

1.	Name of the Bidder	
2.	Address	
3.	Name, designation & address of the person to whom all references shall be made	
4.	Telephone No. (with STD code)	
5.	Mobile No. of the contact person	
6.	Email ID. of the contact person	

Yours faithfully,

(Signature of the Authorized signatory)

Name:

Designation:

Seal:

Date:

Place:

APPLICANT PROFILE FOR TECHNOLOGY TRANSFER

(To be submitted on Bidder Letter Head)

1. Organizations or entrepreneurs interested in providing technology transfer to KAPL may kindly provide background information on their organization/ experience. This information will help KAPL to identify a suitable industry partner for technology transfer.
2. Kindly attach copies of the **annual report, product brochures/ pamphlets**, and any other relevant information along with this form. Add additional sheets if needed.

Sl. No	Organization Background & Experience/Expertise/Facilities
1.	Please state the nature and details of the business carried out at present (please add separately, if needed)
2.	Major projects handled
3.	Company's strength with a brief description of processes handled
4.	Company's human resources and highlight qualification/experience of key technical and managerial
5.	Company's R&D setup, strength & technology
6.	Company's experience in commercializing technology/technology absorption
7.	Please highlight any other relevant information such as synergy in technology or marketing of the product on offer

I/we hereby declare that the information given above is true and correct to the best of my/our knowledge and belief.

Thanking you,

Yours faithfully,

(Signature of the Authorized signatory)

Name:

Designation:

Seal:

Date:

Place:

STRENGTHS & MERITS OF THE APPLICANT

(To be submitted on Bidder Letter Head)

The applicant may submit the following details to highlight the strength and merits of the applicant. Attach an additional sheet, if required.

- 1. Do you have any experience in handling of Technology Transfer projects of this kind? Yes /No**

- 2. If Yes, kindly share the details**

- 3. Kindly share your plan of action to accomplish this technology transfer project until commercialization.**

- 4. What is your plan for scaling up?**

- 5. How will the pilot batches to be undertaken?**

- 6. What support do you anticipate from KAPL?**

I/we hereby declare that the information given above is true and correct to the best of my/our knowledge and belief.

Thanking you,

Yours faithfully,

(Signature of the Authorized signatory)

Name:

Designation:

Seal:

Date:

Place:

UNDERTAKING WITH REGARD TO BLACKLISTING

(To be submitted on Bidder Letter Head)

To,
HOD Purchase
Karnataka Antibiotics and Pharmaceuticals Limited
Plot No.14, II Phase,
Peenya Industrial Area,
Bangalore-560 058.
India

Subject: Undertaking regarding Blacklisting/Non-Debarment

Ref. No. Ref: GTENO. dated 2023

Sir,

It is here by confirmed and declared that M/s _____ is Not blacklisted/debarred by any Government Department/Public Sector Undertaking/Private Sector/or any other agency for which works/assignments/services have been executed/undertaken.

Yours faithfully,

(Signature of the Authorized signatory)

Name:

Designation:

Seal:

Date:

Place:

Note: Any discrepancy found in the undertaking shall be liable for cancellation of the License and Forfeiting of paid license fee.

UNDERTAKING WITH REGARD TO NON-LITIGATION
(To be submitted on Bidder Letter Head)

To,
HOD Purchase
Karnataka Antibiotics and Pharmaceuticals Limited
Plot No.14, II Phase,
Peenya Industrial Area,
Bangalore-560 058.
India.

Subject: Undertaking regarding Litigation

Ref. No. Ref: GTE No..... dated 2023

Sir,

It is here by confirmed and declared that M/s-----,
does not have any litigation/arbitration history with any Government department/ Public
Sector Undertaking/Private Sector/ or any other public authority with which any MoU
was/has been executed/undertaken.

Yours faithfully,

(Signature of the Authorized signatory)

Name:

Designation:

Seal:

Date:

Place:

Note: Any discrepancy found in the undertaking shall be liable for cancellation of the License
and Forfeiting of paid license fee.

PRICE BID*(To be submitted on Bidder Letter Head)*

Name of the Tenderer	
Address of the Tenderer	
Communication address of the Tenderer	
Email / Fax / Telephone No.	
Name of the authorized signatory	

Rates to be quoted for INR/USD/Euro

- I) Name of the Project: Technology Transfer for Cephalosporin-c (Intermediate) & 7-Aminocephalosporanic Acid (7-ACA) Bulk drug project.
- II) The rate quoted by the bidder should be FOR/CIF Destination basis for delivery in Bengaluru/Ujjain or anywhere in India.
 - 1) The quoted rate shall remain firm throughout the period of the contract, i.e. it shall remain constant, notwithstanding any changes to the tax structure, input costs etc.
 - 2) In case of any discrepancy in the rates quoted in Figures and Words, the rates in Words will prevail.

S.No.	Description Item	Price		
		Currency (INR/Dollar/ Euro)	Rate In Figures	Rate in Words
1	Technology Transfer for Cephalosporin-c (Intermediate) & 7-Aminocephalosporanic Acid (7-ACA) Enzymatic Process Bulk drug project – Lab Scale at Innovator Place, Lab Scale, Pilot Scale & Commercial Scale in India.			
1.1	Conversation of Cephalosporin-c (Intermediate) to enzymatic & 7 Enzymatic to -Aminocephalosporanic Acid (7-ACA) in lab demo, provide technology with master seed, demo in their lab, providing technical support to Indian counterpart for Ceph C to enzymatic and enzymatic to 7 ACA product in lab demo, support for pilot plant and commercial batch and also providing necessary document, dossier with required testing reports for transfer of Master seed and technology			

1.2	Indian partner will be responsible for adopting the technology doing lab demonstration in India, demonstration of pilot plant and as well as ten commercial exhibit and scale up in commercial batch in commercial plant for 10 exhibit batches with providing necessary raw material , instrument and process equipment and subject matter expert with required skill for lab demo and pilot plant in Indian partner lab and pilot plant. However 10 commercial exhibit batches will be taken out at KAPL commercial plant at VUI, Ujjain			
1.3	Indian partner should be responsible for necessary process engineering based on process technology , automation, process equipment capacity and specification, process P&ID from Ceph C to enzymatic to 7-ACA including raw material specification, raw material consumption, utilites, quality and quantity requirement, stage wise process critical parameter, process providing to KAPL. Providing training to KAPL team for production, process, QA , QC documentation etc.			
1.4	All equipment sizing and QC equipment require should be suitable for 1000 Mt/Year 7 ACA production			
Note	KAPL have the option to pay fee to innovator directly or through Indian partner. However break up should be provided for necessary government approval.			
	Rate are inclusive of packing /forwarding charges, insurance charges, freight, handling charges, Travelling/Visiting Charges, all other ancillary charges, all central and local taxes, levies and duties on for destination basis.			

I/We have carefully gone through the Tender terms & conditions and agree to abide by them and have quoted the rate(s) above in pursuant there-to.

Yours faithfully,

(Signature of the Authorized signatory)

Name:

Designation:

Seal:

Date:

Place:

SELF DECLARATION CERTIFICATE

(To be given in bidder's letter head)

Ref: KAPL Tender No. _____ Dated _____

"I have read the clause regarding restrictions on procurement from a bidder of a country which shares a land border with India; I certify that this bidder is not from such a country or, if from such a country, has been registered with the Competent Authority, I hereby certify that this bidder fulfills all requirements in this regard and is eligible to be considered. [Where applicable, evidence of valid registration by the Competent Authority shall be attached]".

(Signature of the Authorized signatory)

Name:

Designation:

Seal:

Date:

Place:

The following documents are to be enclosed:

Sl. No.	Documents required	Type of document attached	Page No.
1.	Copies of documents defining the constitution and legal status of the tenderer		
2.	Pamphlet or Brochure		
3.	Certificate from the Chartered Accountant/Certified Accountant of country/Audited Balance sheets for the last three financial years, Income Tax return.		
4.	Authorization Letter	As per format –1	
5.	Declaration	As per format –2	
6.	Applicant Profile for Technology Transfer	As per format –3	
7.	Strength & Merits of the Applicant	As per format -4	
8.	Undertaking on the Letter Head regard to black listing	As per format –5	
9.	Undertaking with regard to Non-Litigation	As per format –6	
10.	Price Bid	As per format –7	
11.	Self Declaration Certificate	As per format –8	
12.	Any accredited certifications (If applicable)		

I/we hereby declare that my/our GTE is made in good faith, and the information contained is true and correct to the best of my/our knowledge and belief.

Thanking you,

Yours faithfully,

(Signature of the Authorized signatory)

Name:

Designation:

Seal:

Date:

Place:

15. TERMS OF PAYMENT

- 15.1. 15% against Advance Bank Guarantee/Letter of Credit along with order valid till the ten successful commercial validation batches are established.
- 15.2. 10% on due diligence of the process – to understand the technological requirement and furnishing all technical information required during the project installation stage.
- 15.3. 10% after conducting successful lab trials at the innovator place.
- 15.4. 15% on transfer of technology documents. After successful Technology verification at the innovator end and after payment, they should hand over the master seed / Microbiology developed culture /Strain).
- 15.5. 10% after conducting a successful Lab Scale in India.
- 15.6. 10% after conducting a successful Pilot Scale in India.
- 15.7. 10% after conducting three successful commercial validation batches.
- 15.8. 10% after conducting seven successful commercial validation batches.
- 15.9. 10% against Bank Guarantee after extended support after one year from the first successful commercial validation batch.
- 15.10. Payment terms are negotiable but subject to KAPL management discretion.

16. LIQUIDATED DAMAGE

- 16.1. If the project is not completed within the agreed timeline, the service provider will have to pay the penalty charges as per the agreed tender terms.
- 16.2. In the event of delay of the project within the stipulated delivery schedule, we may, at our option, either (a) recover from you liquidated damages@0.5% of the project value for every week or part thereof delay, subject to a maximum of @5.0% of the total order value or (b) cancel the order at your risk and cost and recover the extra expenditure incurred by us in completing of the project from the alternate source. The manner and method of repurchase will be at KAPL discretion only.
- 16.3. After handing over the facility to the technology provider, the vendor shall establish three successful commercial validation batches within 90 days. In case, if the vendor fails to do so LD charges shall be applicable as indicated above.

17. OTHER CONDITIONS

- 17.1. The technology should be demonstrated at the site at atleast three validation batch meeting all required specification criteria.
- 17.2. As and when required, if there is a failure in the batch, the transferring site should assist KAPL for at least one year.
- 17.3. If the claim value is not achieved, the payment should be returned to KAPL.